Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 1,904 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: AstraZeneca Clear all

Conditions: Liver Cirrhosis
Interventions: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas

Conditions: Schizophrenia
Interventions: AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Garden Grove, California • Glendale, California • Rockville, Maryland

Conditions: GERD, Acid Reflux Disease, Heartburn, Regurgitation
Interventions: AZD3355, Placebo, Gelusil®; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 84
States / cities: Athens, Alabama • Tucson, Arizona • Little Rock, Arkansas + 81 more

Conditions: Healthy Volunteers, Mass Balance Study
Interventions: AZD3293; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: Benralizumab (Medi-563), Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 100
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more

Conditions: Metastatic Colorectal Cancer
Interventions: Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Conditions: Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
Interventions: NXY-059; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 98
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 95 more

Conditions: Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
Interventions: Not listed
Lead sponsor: MedImmune LLC; Industry
Eligibility: 50 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Denver, Colorado + 18 more

Conditions: Healthy Participants
Interventions: AZD6234, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 142 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Lung Cancer Patients, Caregivers
Interventions: There are no interventions in this study. All participants complete online surveys.; Other
Lead sponsor: LUNGevity Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, long acting release, exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 24
States / cities: Encino, California • La Jolla, California • San Diego, California + 21 more

Conditions: Healthy Participants
Interventions: Baxdrostat, Itraconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy Volunteers
Interventions: MCC-based 13% drug loaded tablets, Mannitol-based 38% drug-loaded tablet; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Asthma
Interventions: Tezepelumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Newport Beach, California • Newark, Delaware • Loxahatchee Groves, Florida + 4 more

Conditions: EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: Osimertinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Athens, Georgia • Atlanta, Georgia • Boston, Massachusetts

Conditions: GERD
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 19
States / cities: Tucson, Arizona • Anaheim, California • Orange, California + 16 more

Conditions: Healthy
Interventions: AZD8418, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Durvalumab, Stereotactic Body Radiation Therapy (SBRT), Standard of Care Therapy; Drug · Radiation · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado

Conditions: Diabetes Prevention in Women After GDM Who Are at High-risk
Interventions: DAPA/MET XR, DAPA, MET XR; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Santa Rosa, California • Muncie, Indiana • Boston, Massachusetts + 6 more

Conditions: Haematological Malignancies
Interventions: AZD0466, Voriconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Tesaglitazar; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Metastatic Colorectal Cancer
Interventions: AZD1775, Irinotecan; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Familial Hypercholesterolemia
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • Hyde Park, New York • Cincinnati, Ohio + 1 more

Search by objective public record fields.

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants

A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib

Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin